Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 153
- Registration Number
- NCT02352753
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 51
- Registration Number
- NCT02348879
Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France
Completed
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- Drug: AMG 162 - Prolia
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 777
- Registration Number
- NCT02347865
- Locations
- 🇫🇷
Amgen, Paris, France
Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid Arthritis
Phase 4
Terminated
- Conditions
- Persistence to Enbrel
- Interventions
- Behavioral: Personalized Patient Counselling
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 19
- Registration Number
- NCT02346877
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 54
- Registration Number
- NCT02345408
- Locations
- 🇳🇱
Netherland, Rotterdam, Netherlands
Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis
Phase 3
Completed
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 28
- Registration Number
- NCT02341417
- Locations
- 🇺🇦
Research Site, Kyiv, Ukraine
Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 107
- Registration Number
- NCT02335983
- Locations
- 🇺🇸
Saint Francis Hospital Cancer Center, Greenville, South Carolina, United States
🇺🇸Greenville Health System, Greenville, South Carolina, United States
🇺🇸Morton Coleman, MD, New York, New York, United States
Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR
Completed
- Conditions
- Metastatic Colorectal Cancer
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 218
- Registration Number
- NCT02322736
- Locations
- 🇬🇷
Research Site, Thessaloniki, Greece
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT02318407
A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 207
- Registration Number
- NCT02307513
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸University of Pennsylvania Health Systems, Philadelphia, Pennsylvania, United States
🇮🇱Bnai Zion Medical Center, Haifa, Israel
© Copyright 2025. All Rights Reserved by MedPath